De Mauri Mackie
About De Mauri Mackie
De Mauri Mackie serves as the Lead, RWE, Global HEOR at Amylyx Pharmaceuticals, bringing a strong background in immunology and extensive experience in scientific strategy and communication. Mackie holds a B.A. in Biochemistry from the University of Pennsylvania and a Ph.D. in Cellular and Molecular Medicine from Johns Hopkins University.
Current Role at Amylyx Pharmaceuticals
De Mauri Mackie serves as the Lead for Real-World Evidence (RWE) and Global Health Economics and Outcomes Research (HEOR) at Amylyx Pharmaceuticals. In this role, which began in 2023, Mackie focuses on integrating real-world data into the company's strategic initiatives. The position is based in Philadelphia, Pennsylvania, and allows for remote work. Mackie's responsibilities include developing scientific strategies that align with the company's goals in health outcomes research.
Education and Expertise
Mackie holds a Bachelor of Arts in Biochemistry from the University of Pennsylvania, where they studied from 2002 to 2006. Following this, they pursued a Doctor of Philosophy in Cellular and Molecular Medicine at The Johns Hopkins University School of Medicine, completing their studies in 2016. This educational background provides a strong foundation in scientific strategy and communication, as well as expertise in evidence, value, and outcomes research, essential for their current role.
Professional Background
Mackie's professional journey includes various roles that contribute to their expertise in health outcomes and research methodology. They worked as a Research Technician at the University of Southern California from 2006 to 2008. Subsequently, they served as a Fellow in Clinical Research Methodology at Worldwide Clinical Trials from 2016 to 2019. Mackie then transitioned to Kantar Health as a Manager in Health Outcomes from 2019 to 2021, before taking on the role of Evidence Generation Lead at Cerner Enviza until 2023.
Research and Scientific Focus
Mackie has a strong background in immunology research, which enhances their capabilities in scientific strategy and communication. This focus supports their work in health economics and outcomes research, allowing them to leverage their academic and professional experiences effectively. Their expertise in real-world evidence is critical for addressing the complexities of health outcomes in the pharmaceutical industry.